Trending NewsTrending NewsNYSE:BMY Bristol Myers Squibb (BMY) Stock Price, News & Analysis $62.65 -0.21 (-0.33%) Closing price 09/30/2026 03:59 PM EasternExtended Trading$62.95 +0.29 (+0.47%) As of 09/30/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Bristol Myers Squibb Stock (NYSE:BMY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bristol Myers Squibb alerts:Sign Up Key Stats Today's Range$62.40▼$64.1350-Day Range$61.14▼$68.0652-Week Range$42.52▼$68.64Volume15.83 million shsAverage Volume10.86 million shsMarket Capitalization$127.98 billionP/E Ratio13.80Dividend Yield4.02%Price Target$67.06Consensus RatingModerate Buy Company Overview Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets. Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors. Its newer and specialized products include Breyanzi, a cell therapy for certain blood cancers; Camzyos, a cardiovascular medicine; and Sotyktu, an immunology treatment. The company also develops investigational therapies through internal research and collaborations. The company traces its history to the formation of Bristol-Myers in 1889 and the founding of the E.R. Squibb & Sons pharmaceutical business in 1858. Bristol-Myers Squibb was created through the 1989 merger of the two companies. Its corporate headquarters are in Princeton, New Jersey. Christopher Boerner has served as chief executive officer since November 2023.AI Generated. May Contain Errors. Read More Bristol Myers Squibb Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks93rd Percentile Overall ScoreBMY MarketRank™: Bristol Myers Squibb scored higher than 93% of companies evaluated by MarketBeat, and ranked 23rd out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.9 / 5Analyst RatingModerate Buy Consensus RatingBristol Myers Squibb has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on 2 strong buy ratings, 13 buy ratings, 10 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Bristol Myers Squibb is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageBristol Myers Squibb has been the subject of 21 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Bristol Myers Squibb's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth-7.05% Earnings GrowthEarnings for Bristol Myers Squibb are expected to decrease by -7.05% in the coming year, from $6.95 to $6.46 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bristol Myers Squibb is 13.80, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.47.Price to Earnings Ratio vs. SectorThe P/E ratio of Bristol Myers Squibb is 13.80, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.68.Price to Earnings Growth RatioBristol Myers Squibb has a PEG Ratio of 0.30. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioBristol Myers Squibb has a P/B Ratio of 6.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Bristol Myers Squibb's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.06% of the float of Bristol Myers Squibb has been sold short.Short Interest Ratio / Days to CoverBristol Myers Squibb has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Bristol Myers Squibb has recently decreased by 4.77%, indicating that investor sentiment is improving. Dividend5.0 / 5Dividend StrengthStrong Dividend LeadershipBristol Myers Squibb is a leading dividend payer. It pays a dividend yield of 4.01%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthBristol Myers Squibb has been increasing its dividend for 17 years.Dividend CoverageThe dividend payout ratio of Bristol Myers Squibb is 55.51%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Bristol Myers Squibb will have a dividend payout ratio of 39.01% next year. This indicates that Bristol Myers Squibb will be able to sustain or increase its dividend.Read more about Bristol Myers Squibb's dividend. News and Social Media3.7 / 5News Sentiment0.90 News SentimentBristol Myers Squibb has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 38 news articles for Bristol Myers Squibb this week, compared to 9 articles on an average week.Search InterestOnly 55 people have searched for BMY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows31 people have added Bristol Myers Squibb to their MarketBeat watchlist in the last 30 days. This is an increase of 41% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Bristol Myers Squibb insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $33,750.00 in company stock.Percentage Held by Insiders0.05% of the stock of Bristol Myers Squibb is held by insiders.Percentage Held by Institutions76.41% of the stock of Bristol Myers Squibb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bristol Myers Squibb's insider trading history. Receive BMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bristol Myers Squibb and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BMY Stock News HeadlinesU.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic ...September 30 at 6:51 PM | marketscreener.comMU.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb's CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*September 30 at 5:32 PM | businesswire.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. | Porter & Company (Ad)Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to KnowSeptember 30 at 1:50 PM | finance.yahoo.comBristol Myers Squibb’s Dividend Sustainability Hinges on One Critical Cash Flow MetricSeptember 30 at 1:50 PM | 247wallst.comBMY Expands Real-World Cancer Data With New AUGTYRO Study in KoreaSeptember 30 at 12:51 PM | tipranks.comBristol-Myers Squibb’s Real‑World Luspatercept Study Wraps Up, Setting the Stage for Next Growth MovesSeptember 30 at 12:31 PM | tipranks.comBristol Myers Squibb's Dividend Sustainability Hinges on One Critical Cash Flow MetricSeptember 30 at 11:45 AM | 247wallst.comSee More Headlines BMY Stock Analysis - Frequently Asked Questions How have BMY shares performed this year? Bristol Myers Squibb's stock was trading at $53.93 at the start of the year. Since then, BMY stock has increased by 16.2% and is now trading at $62.6540. How were Bristol Myers Squibb's earnings last quarter? Bristol Myers Squibb Company (NYSE:BMY) issued its quarterly earnings data on Thursday, July, 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.60 by $0.44. The firm's revenue was up 5.7% compared to the same quarter last year. Read the conference call transcript. When did Bristol Myers Squibb's stock split? Shares of Bristol Myers Squibb split on the morning of Thursday, June 26th 2014.The 2-1 split was announced on Thursday, June 19th 2014. The newly issued shares were distributed to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. Does Bristol Myers Squibb have any subsidiaries? The following companies are subsidiaries of Bristol Myers Squibb: MyoKardia, Forbius, Celgene, IFM Therapeutics, Cormorant Pharmaceuticals, Padlock Therapeutics, Cardioxyl Pharmaceuticals, and others. How do I buy shares of Bristol Myers Squibb? Shares of BMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bristol Myers Squibb own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bristol Myers Squibb investors own include Chevron (CVX), Comcast (CMCSA), McKesson (MCK), Charles Schwab (SCHW), Edwards Lifesciences (EW), Yum! Brands (YUM) and Toronto Dominion Bank (TD). Company Calendar Record date for 8/3 Dividend7/02/2026Ex-Dividend for 8/3 Dividend7/02/2026Last Earnings7/30/2026Dividend Payable8/03/2026Today9/30/2026Record date for 11/2 Dividend10/02/2026Ex-Dividend for 11/2 Dividend10/02/2026Next Earnings (Estimated)10/29/2026Dividend Payable11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 BMY's financial health is in the Green zone, according to TradeSmith. BMY has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:BMY CIK14272 Webwww.bms.com Phone(609) 252-4621Fax212-546-4020Employees32,500Year Founded1887Price Target and Rating Average Price Target for Bristol Myers Squibb$67.06 High Price Target$82.00 Low Price Target$40.00 Potential Upside/Downside+7.0%Consensus RatingModerate Buy Rating Score (0-4)2.62 Research Coverage26 Analysts Profitability EPS (Trailing Twelve Months)$4.54 Trailing P/E Ratio13.80 Forward P/E Ratio9.01 P/E Growth0.3Net Income$7.05 billion Net Margins18.87% Pretax Margin24.21% Return on Equity66.90% Return on Assets14.74% Debt Debt-to-Equity Ratio1.89 Current Ratio1.53 Quick Ratio1.38 Sales & Book Value Annual Sales$48.19 billion Price / Sales2.66 Cash Flow$8.11 per share Price / Cash Flow7.73 Book Value$9.09 per share Price / Book6.89Miscellaneous Outstanding Shares2,042,710,000Free Float2,041,694,000Market Cap$127.98 billion OptionableOptionable Beta0.23 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NYSE:BMY) was last updated on 10/1/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bristol Myers Squibb Company Please log in to your account or sign up in order to add this asset to your watchlist. Share Bristol Myers Squibb With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BMY Stock Alerts